PubMed Health⌕ Search

PubMed · 12662629

Improved learning algorithms for mixture of experts in multiclass classification.

Abstract

Mixture of experts (ME) is a modular neural network architecture for supervised learning. A double-loop Expectation-Maximization (EM) algorithm has been introduced to the ME architecture for adjusting the parameters and the iteratively reweighted least squares (IRLS) algorithm is used to perform maximization in the inner loop [Jordan, M.I., Jacobs, R.A. (1994). Hierarchical mixture of experts and the EM algorithm, Neural Computation, 6(2), 181-214]. However, it is reported in literature that the IRLS algorithm is of instability and the ME architecture trained by the EM algorithm, where IRLS algorithm is used in the inner loop, often produces the poor performance in multiclass classification. In this paper, the reason of this instability is explored. We find out that due to an implicitly imposed incorrect assumption on parameter independence in multiclass classification, an incomplete Hessian matrix is used in that IRLS algorithm. Based on this finding, we apply the Newton-Raphson method to the inner loop of the EM algorithm in the case of multiclass classification, where the exact Hessian matrix is adopted. To tackle the expensive computation of the Hessian matrix and its inverse, we propose an approximation to the Newton-Raphson algorithm based on a so-called generalized Bernoulli density. The Newton-Raphson algorithm and its approximation have been applied to synthetic data, benchmark, and real-world multiclass classification tasks. For comparison, the IRLS algorithm and a quasi-Newton algorithm called BFGS have also been applied to the same tasks. Simulation results have shown that the use of the proposed learning algorithms avoids the instability problem and makes the ME architecture produce good performance in multiclass classification. In particular, our approximation algorithm leads to fast learning. In addition, the limitation of our approximation algorithm is also empirically investigated in this paper.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Chen, L Xu, H Chi. 1999. Improved learning algorithms for mixture of experts in multiclass classification.. https://doi.org/10.1016/s0893-6080(99)00043-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗